Duration:
1 minute and 16 seconds
Views:
26
(1
embedded)
Peregrine Pharmaceuticals Inc - PPHM - reported preliminary results related with its Bavituximab from a randomized Phase II trial showing a 50% improvement in overall tumor response rates in non-small cell lung cancer patients